Crown Bioscience recently announced that Amar Thyagarajan, Ph.D., and Sandeep Sinha, Ph.D., will be joining its leadership team. Read More »

Genmab recently announced that its data from the Phase III CASTOR study of daratumumab, which was presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting and at the 21st Congress of the European Hematology Association (EHA), has been published by the New England Journal of Medicine. Read More »

TG Therapeutics Inc. recently announced that it has received orphan drug designation for TG-1101, otherwise known as ublituximab, from the U.S. Food and Drug Administration (FDA). Read More »

Mallinckrodt plc, a specialty pharmaceutical company and a worldwide leader, has announced that the U.S. Food and Drug Administration (FDA) has granted its Investigational New Drug (IND) application for Synacthen Depot Fast Track designation. Read More »

Therapy combines Vigil engineered autologous tumor cells with durvalumab. Read More »

Pfizer Inc. has announced that it has reached an agreement with AstraZeneca for the acquisition of the development and commercialization rights to its late-stage small molecule anti-infectives business. Read More »

NLS Pharma Group this week announced that it has begun enrollment for its Phase II clinical trial for Mazindol, which will be conducted on adults with DSM-5 Attention Deficit Hyperactivity Disorder (ADHD). Read More »

QIV flu vaccine protects against four common flu strains to maximize immunity during flu season. Read More »

A ballot initiative supporters claim will lower drug prices in California is vague and poorly conceived, said a group with a long history of advocating for better cures and treatment for HIV and hepatitis C. Read More »

CVS Health Corp. has announced that its President and CEO Larry Merlo will be giving a speech to investors at the Morgan Stanley Global Healthcare Conference on Sept. 13. Read More »

Program designs synthetic oligonucleotide-based drug candidates for cancer and rare disease treatments. Read More »

Portola Pharmaceuticals Inc. has announced that the Late-Breaking Science Hot Line session at the European Society of Cardiology (ESC) 2016 Congress featured the interim results of its ongoing Phase 3b/4 ANNEXA-4 clinical trial of AndexXa (andexanet alfa). Read More »

New life-saving diagnostic test recognized at the 2016 JOB/ACNBH Conference in Paris, France. Read More »

Adding Prolia to glucocorticoid therapy increases bone mineral density. Read More »